{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:31:59Z","timestamp":1793118719607,"version":"4.5.0"},"reference-count":49,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>The gabapentinoids were reclassified as Schedule II medications and Class C drugs in the UK in 2019 due to their potential misuse. In this study we examined deaths following gabapentinoid use in England reported to the National Programme on Substance Abuse Deaths.<\/jats:p><jats:p>A total of 3051 deaths were reported (gabapentin: 913 cases; pregabalin: 2322 cases [both detected in 184 cases]). Prescribed and illicitly obtained gabapentinoids accounted for similar proportions of deaths (gabapentin illicit 38.0%, prescribed 37.1%; pregabalin illicit 41.0%, prescribed 34.6%). Opioids were co\u2010detected in most cases (92.0%), and co\u2010prescribed in a quarter (25.3%). Postmortem blood gabapentinoid concentrations were commonly (sub)therapeutic (65.0% of gabapentin cases; 50.8% of pregabalin cases). In only two cases was gabapentinoid toxicity alone attributed in causing death.<\/jats:p><jats:p>Gabapentinoids alone rarely cause death. Clinically relevant doses can, however, prove fatal, possibly by reducing tolerance to opioids. Doctors and patients should be aware of this interaction.<\/jats:p><jats:p>Gabapentinoid\u2013opioid co\u2010prescribing needs urgent revision.<\/jats:p>","DOI":"10.1111\/bcp.15352","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T09:15:12Z","timestamp":1650273312000},"page":"3911-3917","source":"Crossref","is-referenced-by-count":47,"title":["Fatalities associated with gabapentinoids in England (2004\u20132020)"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-9243","authenticated-orcid":false,"given":"Nicola J.","family":"Kalk","sequence":"first","affiliation":[{"name":"Department of Addictions, Institute of Psychiatry, Psychology &amp; Neuroscience King's College London  London UK"},{"name":"South London and Maudsley NHS Foundation Trust, KCH Alcohol Care Team  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching\u2010Ting","family":"Chiu","sequence":"additional","affiliation":[{"name":"Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasa","family":"Sadoughi","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, St George's University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heli","family":"Baho","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, St George's University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn D.","family":"Williams","sequence":"additional","affiliation":[{"name":"Royal Free Hospital NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2557-1710","authenticated-orcid":false,"given":"David","family":"Taylor","sequence":"additional","affiliation":[{"name":"South London and Maudsley NHS Foundation Trust, KCH Alcohol Care Team  London UK"},{"name":"Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-1402","authenticated-orcid":false,"given":"Caroline S.","family":"Copeland","sequence":"additional","affiliation":[{"name":"Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science King's College London  London UK"},{"name":"Population Health Research Institute, St George's University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.7856"},{"key":"e_1_2_12_3_1","volume-title":"British National Formulary 79: April 2020\u2013March 2021","author":"BNF","year":"2020"},{"key":"e_1_2_12_4_1","unstructured":"National Institute for Health and Care Excellence.Neuropathic pain in adults: pharmacological management in non\u2010specialist settings.2017.https:\/\/www.nice.org.uk\/guidance\/cg173. Accessed April 20 2022."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010609"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.171333"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1704633"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010020\u201001432\u20107"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010017\u20100700\u2010x"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.05.017"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13892"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2020.1734695"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.06.018"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010016\u20100359\u2010y"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2014.04.028"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050324518767445"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.01.018"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1556\u20104029.14021"},{"key":"e_1_2_12_19_1","unstructured":"Advisory Council on the Misuse of Drugs.Advice on the anticonvulsant drugs pregabalin and gabapentin.2018.https:\/\/www.gov.uk\/government\/publications\/advice-on-the-anticonvulsant-drugs-pregabalin-and-gabapentin. Accessed April 20 2022."},{"key":"e_1_2_12_20_1","unstructured":"AtkinsV.Pregabalin and gabapentin to be controlled as class C drugs.2018.https:\/\/www.gov.uk\/government\/news\/pregabalin-and-gabapentin-to-be-controlled-as-class-c-drugs. Accessed April 20 2022."},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13843"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.728"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp13X670615"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2019.1662150"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14819"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211021588"},{"key":"e_1_2_12_27_1","unstructured":"OpenPrescribing.2022.https:\/\/openprescribing.net\/"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12358"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2021.106943"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291711002145"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2016.05.033"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4851"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2021.1965159"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/1556\u20104029.13263"},{"key":"e_1_2_12_35_1","first-page":"339","article-title":"Abuse of pregabalin\u2014results of the postmortem toxicology from 2010 to 2012","volume":"80","author":"Lottner\u2010Nau S","year":"2013","journal-title":"Toxichem Krimtech"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkab070"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkx019"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bku004"},{"key":"e_1_2_12_40_1","unstructured":"NICE.Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain.2021.https:\/\/www.nice.org.uk\/guidance\/ng193. Published April 7 2021. Accessed April 20 2022."},{"issue":"1","key":"e_1_2_12_41_1","first-page":"67","article-title":"The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery","volume":"8","author":"Chen C","year":"2013","journal-title":"Curr Clin Pharmacol"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00414\u2010015\u20101193\u20103"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1556\u20104029.2011.01798.x"},{"key":"e_1_2_12_44_1","first-page":"19","article-title":"Gabapentin related fatality: a case study","volume":"38","author":"Ramoo B","year":"2014","journal-title":"Tox Talk"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536200\u2010000000000\u201000000"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970\u20109185.83672"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2016.03.028"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkz036"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l2147"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp11X593857"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15352","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15352","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T05:03:56Z","timestamp":1692680636000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/bcp.15352"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15352","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]}}}